The development of endocrine therapy for women with breast cancer

Cancer Treatment Reviews

Volumn 39, Issue 5, 2013, Pages 507-517

  Sainsbury, Richard ^a  

^a PRINCESS ANNE HOSPITAL   (United Kingdom)

Author keywords

Anastrozole; Aromatase inhibitors; Breast cancer; Endocrine therapy; Exemestane; Fulvestrant; Letrozole; Luteinising hormone releasing hormone; Oestrogen receptor; Tamoxifen

Indexed keywords

AMINOGLUTETHIMIDE; ANASTROZOLE; BUSERELIN; DROLOXIFENE; EXEMESTANE; FULVESTRANT; GOSERELIN; IDOXIFENE; LETROZOLE; LEUPRORELIN; MEGESTROL ACETATE; MIPROXIFENE; RALOXIFENE; TAMOXIFEN; TOREMIFENE;

ADVANCED CANCER; BREAST CANCER; BREAST METASTASIS; CANCER ADJUVANT THERAPY; CANCER HORMONE THERAPY; CANCER MORTALITY; CANCER PALLIATIVE THERAPY; CLINICAL PROTOCOL; CLINICAL TRIAL (TOPIC); COST EFFECTIVENESS ANALYSIS; DISEASE FREE SURVIVAL; DRUG APPROVAL; DRUG BINDING; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; EVENT FREE SURVIVAL; FOOD AND DRUG ADMINISTRATION; GOLD STANDARD; HUMAN; META ANALYSIS (TOPIC); OVERALL SURVIVAL; POSTMENOPAUSE; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; TREATMENT DURATION;

ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; FEMALE; HUMANS;

EID: 84876968058     PISSN: 03057372     EISSN: 15321967     Source Type: Journal    
DOI: 10.1016/j.ctrv.2012.07.006     Document Type: Review

References (107)

1. Ferlay J., Shin H.-R., Bray F., Forman D., Mathers C., Parkin D.M. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010, 127:2893-2917.
2. Jemal A., Siegel R., Xu J., Ward E. Cancer Statistics, 2010. CA Cancer J Clin 2010, 60:277-300.
3. Beatson G.T. On the treatment of inoperable cases of carcinoma of the mamma: suggestions for a new method of treatment, with illustrative cases. Lancet 1896, 2:105-107.
4. Huggins C., Berganstal D.M. Inhibition of human mammary and prostatic cancers by adrenalectomy. Cancer Res 1952, 12:134-141.
5. Olivecrona H., Luft R. Experiences with hypophysectomy in cancer of the breast. Ann R Coll Surg Eng 1957, 20:267-279.
6. Adair F.E., Herrmann J.B. The use of testosterone propionate in the treatment of advanced carcinoma of the breast. Ann Surg 1946, 123:1023-1035.
7. Rae I.P. Stilboestrol in late malignant disease of the breast. Glasgow Med J 1948, 29:248-254.
8. Greenspan E.M., Fieber M., Lesnick G., Edelman S. Response of advanced breast cancer to the combination of the anti-metabolite methotrexate and the alkylating agent thiotepa. J Mt Sinai Hosp 1963, 30:246-267.
9. Carter A.C., Sedransk N., Kelley R.M., et al. Diethylstilbestrol: recommended dosages for different categories of breast cancer patients. Report of the Cooperative Breast Cancer Group. JAMA 1977, 237:2079-2085.
10. Cline J.W. Cancer studies. Cancer of the breast. Cal Med 1963, 99:393-402.
11. Cole M.P., Jones C.T., Todd I.D. A new anti-oestrogenic agent in late breast cancer. An early clinical appraisal of ICI46474. Br J Cancer 1971, 25:270-275.
12. Osborne C.K. Tamoxifen in the treatment of breast cancer. N Engl J Med 1998, 339:1609-1618.
13. Burstein H.J., Prestrud A.A., Seidenfeld J., et al. American Society of Clinical Oncology Clinical Practice Guideline: update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer. J Clin Oncol 2010, 28:3784-3796.
14. Ingle J.N., Ahmann D.L., Green S.J., et al. Randomized clinical trial of diethylstilbestrol versus tamoxifen in postmenopausal women with advanced breast cancer. N Engl J Med 1981, 304:16-21.
15. Stewart H.J., Forrest A.P., Gunn J.M. The tamoxifen trial a double-blind comparison with stilboestrol in postmenopausal women with advanced breast cancer. Eur J Cancer 1980, (Suppl 1):83-88.
16. Westerberg H. Tamoxifen and fluoxymesterone in advanced breast cancer: a controlled clinical trial. Cancer Treat Rep 1980, 64:117-121.
17. Ward H.W. Anti-oestrogen therapy for breast cancer: a trial of tamoxifen at two dose levels. Br Med J 1973, 1:13-14.
18. Manni A., Arafah B., Pearson O.H. Estrogen and progesterone receptors in the prediction of response of breast cancer to endocrine therapy. Cancer 1980, 46(Suppl 12):2838-2841.
19. Fisher B., Jeong J.H., Dignam J., et al. Findings from recent National Surgical Adjuvant Breast and Bowel Project adjuvant studies in stage I breast cancer. J Natl Cancer Inst Monogr 2001, 62-66.
20. Controlled trial of tamoxifen as single adjuvant agent in management of early breast cancer. Analysis at six years. Lancet 1985, 325:836-840. The Nolvadex Adjuvant Trial Organisation.
21. Fisher B., Costantino J., Redmond C., et al. A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumors. N Engl J Med 1989, 320:479-484.
22. Dignam J.J., Bryant J., Wieand H.S., Fisher B., Wolmark B. Early stopping of a clinical trial when there is no evidence of no treatment benefit: protocol B-14 of the National Surgical Adjuvant Breast and Bowel Project. Control Clin Trials 1998, 19:575-588.
23. Fisher B., Dignam J., Bryant J., Wolmark N. Five versus more than five years of tamoxifen for lymph node-negative breast cancer: updated findings from the national surgical adjuvant breast and bowel project B-14 randomized trial. J Natl Cancer Inst 2001, 93:684-690.
24. Stewart H.J. The Scottish trial of adjuvant tamoxifen in node-negative breast cancer. Scottish Cancer Trials Breast Group. J Natl Cancer Inst Monogr 1992, 117-120.
25. Stewart H.J., Prescott R.J., Forrest A.P. Scottish adjuvant tamoxifen trial: a randomized study updated to 15years. J Natl Cancer Inst 2001, 93:456-462.
26. Pritchard K.I., Thomson D.B., Myers R.E., Sutherland D.J., Mobbs B.G., Meakin J.W. Tamoxifen therapy in premenopausal patients with metastatic breast cancer. Cancer Treat Rep 1980, 64:787-796.
27. Sawka C.A., Pritchard K.I., Paterson A.H., et al. Role and mechanism of action of tamoxifen in premenopausal women with metastatic breast carcinoma. Cancer Res 1986, 46:3152-3156.
28. Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet 1998, 351:1451-1467. Early Breast Cancer Trialists' Collaborative Group.
29. Tamoxifen for early breast cancer (Cochrane Review). The Cochrane Library 2004, 1-38. Early Breast Cancer Trialists' Collaborative Group, The Cochrane Library, Chichester, UK.
30. Lavie O., Barnett-Griness O., Narod S.A., Rennert G. The risk of developing uterine sarcoma after tamoxifen use. Int J Gynecol Cancer 2008, 18:352-356.
31. Fisher B., Costantino J.P., Wickerham D.L., et al. Tamoxifen for prevention of breast cancer: report of the national surgical adjuvant breast and bowel project P-1 study. J Natl Cancer Inst 1998, 90:1371-1388.
32. Cuzick J., Forbes J., Edwards R., et al. First results from the International Breast Cancer Intervention Study (IBIS-I): a randomised prevention trial. Lancet 2002, 360:817-824.
33. Cuzick J., Forbes J.F., Sestak I., et al. Long-term results of tamoxifen prophylaxis for breast cancer - 96-month follow-up of the randomized IBIS-I trial. J Natl Cancer Inst 2007, 99:272-282.
34. Fagerlin A., Zikmund-Fisher B.J., Nair V., et al. Women's decisions regarding tamoxifen for breast cancer prevention: responses to a tailored decision aid. Breast Cancer Res Treat 2010, 119:613-620.
35. Lewis J.D., Chagpar A.B., Shaughnessey E.A., Nurko J., McMasters K., Edwards M.J. Excellent outcomes with adjuvant toremifene or tamoxifen in early stage breast cancer. Cancer 2010, 116:2307-2315.
36. Fareston summary of product characteristics. Available at <>; 2010 [accessed 12.03.12. http://www.medicines.org.uk/emc/medicine/10221/SPC/Fareston+60mg+Tablets.
37. Martino S., Cauley J.A., Barrett-Connor E., et al. Continuing outcomes relevant to Evista: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene. J Natl Cancer Inst 2004, 96:1751-1761.
38. Dickler M.N., Norton L. The MORE trial: multiple outcomes for raloxifen evaluation - breast cancer as a secondary end point: implications for prevention. Ann N Y Acad Sci 2001, 949:134-142.
39. Vogel V.G., Constantino J.P., Wickerham D.L., et al. Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP study of tamoxifen and raloxifene (STAR) P-2 trial. JAMA 2006, 295:2727-2741.
40. Evista prescribing information. Available at <>; 2010 [accessed 12.03.12]. http://www.pi.lilly.com/us/evista-pi.pdf.
41. Vogel V.G., Constantino J.P., Wickerham D.L., et al. Update of the national surgical adjuvant breast and bowel project study of tamoxifen and raloxifene (STAR) P-2 Trial: preventing breast cancer. Cancer Prev Res (Phila) 2010, 3:696-706.
42. Spicer D.V., Pike M.C. Sex steroids and breast cancer prevention. J Natl Cancer Inst Monogr 1994, 139-147.
43. Tan S.H., Wolff A.C. The role of ovarian ablation in the adjuvant therapy of breast cancer. Curr Oncol Rep 2008, 10:27-37.
44. Rabaglio M., Aebi S., Castiglione-Gertsch M. Controversies of adjuvant endocrine treatment for breast cancer and recommendations of the 2007 St Gallen conference. Lancet Oncol 2007, 8:940-949.
45. McDonald Wade S., Hackney M.H., Khatcheressian J., Lyckholm L.J. Ovarian suppression in the management of premenopausal breast cancer: methods and efficacy in adjuvant and metastatic settings. Oncology 2008, 75:192-202.
46. Baum M., Hackshaw A., Houghton J., et al. Adjuvant goserelin in pre-menopausal patients with early breast cancer: results from the ZIPP study. Eur J Cancer 2006, 42:895-904.
47. Hackshaw A., Baum M., Fornander T., et al. Long-term effectiveness of adjuvant goserelin in premenopausal women with early breast cancer. J Natl Cancer Inst 2009, 101:341-349.
48. Jonat W., Kaufmann M., Sauerbrei W., et al. Goserelin versus cyclophosphamide, methotrexate, and fluorouracil as adjuvant therapy in premenopausal patients with node-positive breast cancer: The Zoladex Early Breast Cancer Research Association Study. J Clin Oncol 2002, 20:4628-4635.
49. Kaufmann M., Jonat W., Blamey R., et al. Survival analyses from the ZEBRA study: goserelin (Zoladex™) versus CMF in premenopausal women with node-positive breast cancer. Eur J Cancer 2003, 39:1711-1717.
50. Cuzick J., Ambroisine L., Davidson N., et al. Use of luteinising-hormone-releasing hormone agonists as adjuvant treatment in premenopausal patients with hormone-receptor-positive breast cancer: a meta-analysis of individual patient data from randomised adjuvant trials. Lancet 2007, 369:1711-1723.
51. Karlsson P., Sun Z., Braun D., et al. Long-term results of International Breast Cancer Study Group Trial VIII: adjuvant chemotherapy plus goserelin compared with either therapy alone for premenopausal patients with node-negative breast cancer. Ann Oncol 2011, 22:2216-2226.
52. Miller W.R., Bartlett J., Brodie A.M., et al. Aromatase inhibitors: are there differences between steroidal and nonsteroidal aromatase inhibitors and do they matter?. Oncologist 2008, 13:829-837.
53. Harris A.L., Powles T.J., Smith I.E. Aminoglutethimide in the treatment of advanced postmenopausal breast cancer. Cancer Res 1982, 42(8 Suppl):3405s-3408s.
54. Buzdar A., Jonat W., Howell A., et al. Anastrozole, a potent and selective aromatase inhibitor, versus megestrol acetate in postmenopausal women with advanced breast cancer: results of overview analysis of two phase III trials. Arimidex Study Group. J Clin Oncol 1996, 14:2000-2011.
55. Buzdar A.U., Jonat W., Howell A., et al. Anastrozole versus megestrol acetate in the treatment of postmenopausal women with advanced breast carcinoma: results of a survival update based on a combined analysis of data from two mature phase III trials. Arimidex Study Group. Cancer 1998, 83:1142-1152.
56. Gershanovich M., Chaudri H.A., Campos D., et al. Letrozole, a new oral aromatase inhibitor: randomised trial comparing 2.5mg daily, 0.5mg daily and aminoglutethimide in postmenopausal women with advanced breast cancer. Letrozole International Trial Group (AR/BC3). Ann Oncol 1998, 9:639-645.
57. Dombernowsky P., Smith I., Falkson G., et al. Letrozole, a new oral aromatase inhibitor for advanced breast cancer: double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate. J Clin Oncol 1998, 16:453-461.
58. Nabholtz J.M., Buzdar A., Pollak M., et al. Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. Arimidex Study Group. J Clin Oncol 2000, 18:3758-3767.
59. Bonneterre J., Thürlimann B., Robertson J.F., et al. Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: results of the tamoxifen or arimidex randomized group efficacy and tolerability study. J Clin Oncol 2000, 18:3748-3757.
60. Mouridsen H., Gershanovich M., Sun Y., et al. Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase III study of the International Letrozole Breast Cancer Group. J Clin Oncol 2001, 19:2596-2606.
61. Paridaens R.J., Dirix L.Y., Beex L.V., et al. Phase III study comparing exemestane with tamoxifen as first-line hormonal treatment of metastatic breast cancer in postmenopausal women: the European Organisation for Research and Treatment of Cancer Breast Cancer Cooperative Group. J Clin Oncol 2008, 26:4883-4890.
62. Gltick S. Changing the gold standard in adjuvant therapy for breast cancer: from tamoxifen to aromatase inhibition. Biomed Pharmacother 2005, 59(Suppl 2):S321-S322.
63. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet 2002, 359:2131-2139. The ATAC Trialists' Group.
64. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet 2005, 365:60-62. ATAC Trialists' Group.
65. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med 2005, 353:2747-2757. The Breast International Group (BIG) 1-98 Collaborative Group.
66. Coombes R.C., Hall E., Gibson L.J., et al. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med 2004, 350:1081-1092.
67. Cuzick J., Sestak I., Baum M., et al. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial. Lancet Oncol 2010, 11:1135-1141.
68. Letrozole therapy alone or in sequence with tamoxifen in women with breast cancer. N Engl J Med 2009, 361:766-776. The BIG 1-98 Collaborative International Breast Cancer Study Group.
69. Colleoni M., Giobbie-Hurder A., Regan M., et al. Analyses adjusting for selective crossover show improved overall survival with adjuvant letrozole compared with tamoxifen in the BIG 1-98 study. J Clin Oncol 2011, 29:1117-1124.
70. Dowsett M., Cuzick J., Ingle J., et al. Meta-analysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifen. J Clin Oncol 2010, 28:509-518.
71. Boccardo F., Rubagotti A., Guglielmini P., et al. Switching to anastrozole versus continued tamoxifen treatment of early breast cancer. Updated results of the Italian tamoxifen anastrozole (ITA) trial. Ann Oncol 2006, 17(Suppl 7):vii10-vii14.
72. Jakesz R., Jonat W., Gnant M., et al. Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial. Lancet 2005, 366:455-462.
73. Kaufmann M., Jonat W., Hilfrich J., et al. Improved overall survival in postmenopausal women with early breast cancer after anastrozole initiated after 2years of treatment with tamoxifen compared with continued tamoxifen: the ARNO 95 Study. J Clin Oncol 2007, 25:2664-2670.
74. Jonat W., Gnant M., Boccardo F., et al. Effectiveness of switching from adjuvant tamoxifen to anastrozole in postmenopausal women with hormone-sensitive early-stage breast cancer: a meta-analysis. Lancet Oncol 2006, 7:991-996.
75. BIG 1-98: A prospective randomized double-blind double-dummy phase III study to evaluate letrozole as adjuvant endocrine therapy for postmenopausal women with receptor- positive breast cancer. The Breast 2005, 14(Suppl 1):S3. BIG 1-98 Collaborative Group.
76. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005, 365:1687-1717. Early Breast Cancer Trialists' Collaborative Group.
77. Goss P.E., Ingle J.N., Martino S., et al. Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17. J Natl Cancer Inst 2005, 97:1262-1271.
78. Jakesz R., Greil R., Gnant M., et al. Extended adjuvant therapy with anastrozole among postmenopausal breast cancer patients: results from the randomized Austrian breast cancer and colorectal cancer study group trial 6a. J Natl Cancer Inst 2007, 99:1845-1853.
79. Mamounas E.P., Jeong J.H., Wickerham D.L., et al. Benefit From exemestane as extended adjuvant therapy after 5 years of adjuvant tamoxifen: intention-to-treat.analysis of the national surgical adjuvant breast and bowel project B-33 trial. J Clin Oncol 2008, 26:1965-1971.
80. Wakeling A.E., Dukes M., Bowler J. A potent specific pure antiestrogen with clinical potential. Cancer Res 1991, 51:3867-3873.
81. Howell A., Robertson J.F.R., Quaresma J. Fulvestrant, formerly ICI 182,780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment. J Clin Oncol 2002, 20:3396-3403.
82. Cano A., Matallin P., Legua V., Tortajada M., Bonilla-Musoles F. Tamoxifen and the uterus and endometrium. Lancet 1989, 1:376.
83. Ewer M.S., Glück S. A woman's heart: the impact of adjuvant endocrine therapy on cardiovascular health. Cancer 2009, 115:1813-1826.
84. Santen R.J. Clinical review: effect of endocrine therapies on bone in breast cancer patients. J Clin Endocrinol Metab 2011, 96:308-319.
85. Osborne C.K., Pippen J., Jones S.E., et al. Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: results of a North American trial. J Clin Oncol 2002, 20:3386-3395.
86. Robertson J.F., Osborne C.K., Howell A., et al. Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma in postmenopausal women: a prospective combined analysis of two multicenter trials. Cancer 2003, 98:229-238.
87. Howell A., Robertson J.F.R., Abram P., et al. Comparison of fulvestrant versus tamoxifen for the treatment of advanced breast cancer in postmenopausal women previously untreated with endocrine therapy: a multinational, double-blind, randomized trial. J Clin Oncol 2004, 22:1605-1613.
88. DeFriend D.J., Howell A., Nicholson R.I., et al. Investigation of a new pure antiestrogen (ICI 182780) in women with primary breast cancer. Cancer Res 1994, 54:408-414.
89. Robertson J.F., Nicholson R.I., Bundred N.J., et al. Comparison of the short-term biological effects of 7alpha-[9-(4,4,5,5,5-pentafluoropentylsulfinyl)-nonyl]estra-1,3,5, (10)-triene-3,17beta-diol (Faslodex) versus tamoxifen in postmenopausal women with primary breast cancer. Cancer Res 2001, 61:6739-6746.
90. Di Leo A., Jerusalem G., Petruzelka L., et al. Results of the CONFIRM Phase III trial comparing fulvestrant 250mg with fulvestrant 500mg in postmenopausal women with estrogen receptor-positive advanced breast cancer. J Clin Oncol 2010, 28:4594-4600.
91. Price K.N., Goldhirsch A. Clinical trial update: international breast cancer study group. Breast Cancer Res 2005, 7:252-254.
92. Gnant M., Mlineritsch B., Schippinger W., et al. Endocrine therapy plus zoledronic acid in premenopausal breast cancer. N Engl J Med 2009, 360:679-691.
93. Van Tine B.A., Crowder R.J., Ellis M.J. ER and PI3K independently modulate endocrine resistance in ER positive breast cancer. Cancer Discov 2011, 1:287-288.
94. McCartan D., Bolger J., Fagan A., et al. Global characterization of the SRC-1 transcriptome identifies ADAM22 as an ER-independent mediator of endocrine resistant breast cancer. Cancer Res 2012, 72:220-229.
95. Giuliano M., Schifp R., Osborne C.K., Trivedi M.V. Biological mechanisms and clinical implications of endocrine resistance in breast cancer. Breast 2011, 20(Suppl 3):S42-S49.
96. Bachelot T, Bourgier C, Cropet C, et al. TAMRAD: A GINECO randomized Phase II Trial of everolimus in combination with tamoxifen versus tamoxifen alone in patients (pts) with hormone-receptor positive, HER2 negative metastatic breast cancer (MBC) with prior exposure to aromatase inhibitors (AI). Abstract presented at the San Antonio Breast Cancer Symposium, San Antonio, TX, USA, 8-12 December, 2010 (Abstract S1-6).
97. Baselga J., Campone M., Piccart M., et al. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med 2012, 366:520-529.
98. Osborne C.K., Schiff R. Mechanisms of endocrine resistance in breast cancer. Annu Rev Med 2011, 62:233-247.
99. Osborne C.K., Shou J., Massarweh S., Schiff R. Crosstalk between estrogen receptor and growth factor receptor pathways as a cause for endocrine therapy resistance in breast cancer. Clin Cancer Res 2005, 11:865s-870s.
100. Emde A., Mahlknecht G., Maslak K., et al. Simultaneous inhibition of estrogen receptor and the HER2 pathway in breast cancer: effects of HER2 abundance. Transl Oncol 2011, 4:293-300.
101. Wang Y.C., Morrison G., Gillihan R., et al. Different mechanisms for resistance to trastuzumab versus lapatinib in HER2-positive breast cancers - role of estrogen receptor and HER2 reactivation. Breast Cancer Res 2011, 13:R121.
102. Schwartzberg L.S., Franco S.X., Florance A., O'Rourke L., Maltzman J., Johnston S. Lapatinib plus letrozole as first-line therapy for HER-2+ hormone receptor-positive metastatic breast cancer. Oncologist 2010, 15:122-129.
103. Oh A.S., Lorant L.A., Holloway J.N., Miller D.L., Kern F.G., El-Ashry D. Hyperactivation of MAPK induces loss of ERalpha expression in breast cancer cells. Mol Endocrinol 2001, 15:1344-1359.
104. Bayliss J., Hilger A., Vishnu P., Diehl K., El-Ashry D. Reversal of the estrogen receptor negative phenotype in breast cancer and restoration of antiestrogen response. Clin Cancer Res 2007, 13:7029-7036.
105. Trimarchi M.P., Mouangsavanh M., Huang T.H. Cancer epigenetics: a perspective on the role of DNA methylation in acquired endocrine resistance. Chin J Cancer 2011, 30:749-756.
106. Wang L., Ellsworth K.A., Moon I., et al. Functional genetic polymorphisms in the aromatase gene CYP19 vary the response of breast cancer patients to neoadjuvant therapy with aromatase inhibitors. Cancer Res 2010, 70:319-328.
107. Cancer Research UK. Statistics and outlook for breast cancer. Available at <>; 2011 [accessed 12.03.12]. http://www.cancerhelp.cancerresearchuk.org/type/breast-cancer/treatment/statistics-and-outlook-for-breast-cancer.